Research Library — Page 13 | Reta Compare
402 research articles. Page 13 of 17.
Articles
- Advancements in Retatrutide Research: Trials Show Up to 29% Weight Loss
- Retatrutide Demonstrates Significant Weight Loss Effects in TRIUMPH-4 Trial
- Eli Lilly Explores Pain Relief Potential of Retatrutide Beyond Weight Loss
- Advancements in Retatrutide Research: The GLP-3R Designation Explained
- Advancements in Retatrutide Research: The Introduction of GLP-3R Designation
- Retatrutide Achieves Significant Weight Loss in Phase 3 Clinical Trial
- Examining Weight Loss Outcomes with Retatrutide in Recent Legal Cases
- Exploring the Role of Retatrutide in MC4R Deficient Obesity Treatment
- Exploring the Implications of Retatrutide in the Evolving GLP-1 Landscape
- Retatrutide Compared to New Monthly Obesity Treatment in Rat Studies
- Retatrutide's Potential to Compete with Ozempic in Weight Loss Treatments
- Eli Lilly's Retatrutide Plant Investment and Its Impact on Obesity Research
- Lilly's $3.5 Billion Investment in Retatrutide Production for Obesity Treatment
- Concerns Over Bootlegged Retatrutide Use Highlight Safety Issues
- Exploring Retatrutide: A Key Player Among Future GLP-1 Drugs
- Retatrutide: A New Contender in Weight Management and Metabolic Health
- Retatrutide Achieves Significant Weight Reduction in Phase 3 Clinical Trial
- Exploring Retatrutide: A Potential Advancement in Weight Management Therapy
- Exploring Retatrutide's Role in Osteoarthritis Management: Insights from TRIUMPH-4
- Insights on Retatrutide Trial Results and Their Implications
- Retatrutide's Impact on Weight Loss and Knee Pain in Obesity and Osteoarthritis
- Exploring the Potential of Retatrutide in Chronic Kidney Disease Management
- Retatrutide: Insights from Recent Developments and Market Outlook
- Retatrutide Demonstrates Superior Weight Loss in TRIUMPH-4 Trial Compared to Tirzepatide
- Recent Research Highlights Retatrutide's Efficacy in Weight Loss